ClinicalTrials.gg
CompletedNCT06927752Updated Oct 29, 2026

Retrospective Data Analysis PelviGYNious/EndoGYNious

An observational study in Prolapse, Sacrocolpopexy and Pelvic Organ Prolapse (POP), sponsored by A.M.I. Agency for Medical Innovations GmbH. Completed at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionPelvic Organ ProlapseRegistry: ProlapseReclassifiedWhy we changed it
Registry
Prolapse — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pelvic Organ Prolapse
Why
  1. The study's listed conditions name Pelvic Organ Prolapse, a narrower term within Prolapse.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by A.M.I. Agency for Medical Innovations GmbH · Observational

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
80
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Pelvic Organ Prolapse with a site in Germany — 4 open to participants now, 6 under way, none of them phase 3. Pelvic Organ Prolapse · Germany.

Enrollment
10th of 14
80 · median 113
Started
2024
with 1 other
Observational
14 of 19
2 open now
Registered
17th of 19
by date
Lead sponsor
4 of 19
A.M.I. Agency for Medical Innovations GmbH

Among the 19 studies in Pelvic Organ Prolapse with a site in Germany, this one is the 10th largest by enrollment of the 14 observational ones that give a count, is one of 2 that started in 2024, is one of 14 observational ones, and was the 17th registered.

Pelvic Organ Prolapse

522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.

Browse Pelvic Organ Prolapse studies →

Open to participants now

4 of the 19 studies in Pelvic Organ Prolapse with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Pelvic Organ Prolapse with a site in Germany, or all of them as a file.
02

Study summary

The retrospective patient chart review aims to generate additional data to substantiate the safety and performance of EndoGYNious and PelviGYNious.

03

Conditions studied

  • Prolapse
  • Sacrocolpopexy
  • Pelvic Organ Prolapse (POP)

Browse trials for

Keywords

  • Sacrocolpopexy
  • Sacrocervicopexy
  • surgical mesh
  • laparoscopic mesh
04

In context

Pelvic Organ Prolapse Reclassified

522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.

This study's enrollment of 80 is below the median of 134 across 171 observational studies indexed under Pelvic Organ Prolapse.

Browse Pelvic Organ Prolapse studies →

Lead sponsor

A.M.I. Agency for Medical Innovations GmbH is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Compared within Pelvic Organ Prolapse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Prolapse. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The planned clinical investigation is a retrospective chart review of clinical data.

All patients who underwent surgery between January 2016 and December 2023 and met the inclusion criteria and no exclusion criteria were analyzed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Surgery for POP
  • Implantation of either EndoGYNious or PelviGYNious
  • Concomitant procedures are allowed
  • Women minimum 18 years old
  • Written for surgery

Exclusion criteria

Exclusion Criteria:

Patients who rule out subsequent contact by the hospital will be excluded.

The use of the products is in case of:

  • pregnancy and/or patients who consider future pregnancies
  • adolescent/ pubescent patients
  • existence of a known sensitivity/ allergy against plastic materials such as polypropylene, polyester, etc.
  • any pathology, including known or suspected uterine pathology, which would compromise placement of the implant/mesh (e.g. anatomical distortion or abnormalities)
  • known anticoagulation disorder
  • anticoagulant therapy
  • connective tissue disease
  • renal insufficiency and upper urinary tract obstruction
  • cancer illnesses of the vagina / cervix / rectum
  • undergone radiation therapy on the vagina, cervix, rectum
  • planned or emergency opening of the gastro-intestinal tract, as this could cause a risk of product contamination that could lead to infection that would require removal of the implant/device
  • active or latent infection especially of the genital system and/or urinary tract
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
80 participants (actual)
Patient registry
No

Groups and cohorts

  • EndoGYNious

    Patient received EndoGYNious mesh implant.

    Device: EndoGYNious

  • PelviGYNious

    Patient received PelviGYNious mesh implant.

    Device: PelviGYNious

Interventions

  • DevicePelviGYNious

    Patient received PelviGYNious implant.

  • DeviceEndoGYNious

    Patient received EndoGYNious implant.

07

What researchers measure

Primary outcomes

  1. Patient subjective outcome

    Patient subjective outcome after POP treatment with EndoGYNious or PelviGYNious will be measured with a validated questionnaire (German Pelvic Floor Questionnaire "Deutscher Beckenboden-Fragebogen") . This questionnaire focus on 4 items (bladder, bowel, prolapse, sexuality). Each item has its scores, scores were summed up for each category (bladder max. 45, bowel max. 34, prolapse max. 15, sexual max. 21), Calculation: (achieved value of category/ max. value of category)\*10; max. value 10 for each category, max. final score 40 The postoperative scores will be compared with the preoperative scores.

    Time frame: From baseline to the end of last follow-up [3 months, 12 months]

Secondary outcomes

  1. Postoperative complications

    To analyze postoperative complications in women undergoing POP treatment with EndoGYNious or PelviGYNious during the follow up period. The occurrence of each complicaiton/adverse event will be compared to the occurrence of the same complication by similar products or other state of the art treatments

    Time frame: From baseline to the end of last follow-up [average of minimum 3 months]

  2. Anatomical success (POP-Q)

    POP-Q system according to ICS with POP-Q stages 0, I, II, III, IV The postoperative POP-Q stages (overall, apical compartment, anterior compartment, posterior compartment) will be compared to the preoperative POP-Q stages.

    Time frame: From baseline to the end of last follow-up [average of minimum 3 months]

08

Study locations

1 site
  • Universitätsklinikum Erlangen, Frauenklinik
    Erlangen, Germany
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2024 to primary completion in Dec 2025, 20 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion May 2025 → Dec 2025 and completion Aug 2025 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 15, 2025
StartActual
Apr 1, 2024
Primary completionActual
Dec 31, 2025was May 2025
CompletionActual
Feb 28, 2026was Aug 2025
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 29, 2026
Primary completion
May 2025→Dec 31, 2025 (actual)
Oct 29, 2026
Study completion
Aug 2025→Feb 28, 2026 (actual)
Oct 29, 2026
Eligibility
Revised
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Completed
    Primary completion May 2025→Dec 31, 2025 (now actual)
    Study completion Aug 2025→Feb 28, 2026 (now actual)
    Eligibility Revised
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06927752
Lead sponsor
A.M.I. Agency for Medical Innovations GmbH
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Apr 1, 2024
Primary completion
Dec 31, 2025
Completion
Feb 28, 2026
Last update
Oct 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion